BioSpace News Archive

The Medicines Company will host a conference call and audio webcast on Wednesday, April 25, 2018, at 8:30 a.m., Eastern Time, to discuss first-quarter 2018 financial results and operational developments.

Teva Pharmaceutical Industries [NYSE and TASE: TEVA] has announced that Teva and the Procter & Gamble Company [NYSE: PG] have agreed to terminate the PGT Healthcare partnership that the two companies established in 2011 to market OTC (Over The Counter) medicines.

Omeros Corporation announced that the results of four real-world clinical studies evaluating the benefits of OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% were presented at the American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting held in Washington, D.C., April 13-17, 2018.

FirstLight Home Care is congratulating Brian Anderson, who was recognized by the Franchise Business Review as a 2018 Rockstar Franchisee.

Curaleaf is proud to announce that the company’s processing facility in Florida has earned their Safe Quality Food (SQF) Level II certification with a score of “Excellent”.

D’Amore Healthcare, Inc. announced that it has doubled the number of mental health care beds in its treatment center.

Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-steroidal therapeutics for the treatment of chronic pain, today announced it will present Phase 1 safety and tolerability data of single ascending doses of CNTX-6970 in healthy volunteers and Phase 2b efficacy and safety data of CNTX-4975 for the treatment of moderate to severe osteoarthritis knee pain at the 34th Annual American Academy of Pain Medicine (AAPM) Meeting

Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the “Company” or “Kalytera”) today announced that the U.S. Patent and Trademark Office (“USPTO”) issued U.S. Patent No. 9,889,100 B2 with claims covering the use of cannabidiol (“CBD”) for the treatment of severe and refractory graft versus host disease (“GVHD”)

Gilla Kaplan, Ph.D., retiring from Board of Directors after 20 years of service US health insurance expert Patricia Hemingway Hall elected to Board of Directors Juno Therapeutics co-founder and former CEO Hans Bishop elected to Board of Directors

Partnership Will Help Clients Develop and Enable Strategic Relationships with Key Accounts